Most HBV researchers appear to have settled n that cure is nt achievable and are seeking functional cure but as yiu can see from some of the new research below there appears to be some researchers who still have as their goal a cure…..
over 50 reports so far from EASL, more coming
The International Liver Congress™
EASL - European Association for the
Study of the Liver
June 22-26 2022
EASL: ABI-4334, a novel inhibitor of hepatitis B virus core protein, promotes formation of empty capsids and prevents cccDNA formation by disruption of incoming capsids - (06/30/22)
EASL: Assembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL's International Liver Congress™ 2022 - (06/30/22)
EASL: Long-term HBsAg suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects - (06/30/22)
EASL: Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects (HS) and subjects with chronic hepatitis B (CHB) - (06/30/22)
EASL: Viral nucleic acids suppression activity of RO7049389 plus NUC with/without Peg-IFN in virologically-suppressed and treatment-naïve chronic hepatitis B patients: 48-week treatment and post treatment follow up - (06/30/22)
EASL: Continued suppression of viral markers observed following discontinuation of nucleos(t)ide analogue therapy in chronic hepatitis B subjects with low hepatitis B surface antigen levels after 48 weeks of treatment with AB-729 - (06/30/22)
EASL: Hepatitis B virus antigen reduction effect of RO7049389 plus NUC with/without Peg-IFN in chronic hepatitis B patients - (06/27/22)
EASL: Evidence of Past Hepatitis C and D Co-Infection in Hepatitis B Seronegative Individuals - (06/27/22)
EASL: EASL 2022 HBV, HDV Wrap-Up - (06/27/22)
EASL: Effects of the siRNA JNJ-3989 and/or the Capsid Assembly Modulator JNJ-6379 on Viral Markers of Chronic Hepatitis B: Results From the REEF-1 Study - (06/27/22)
EASL: Peginterferon Lambda (IFN-λ) combined with Lonafarnib diminished triphasic HDV kinetic pattern seen under IFN-λ monotherapy: The LIFT-1 Study - (06/27/22)
EASL: Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL's International Liver Congress™ - (06/27/22)
EASL: The disease burden of hepatitis B and C from 2015- 2030: The long and winding road towards elimination - (06/27/22)
EASL: The Global Burden of Liver Cancer (LC) and Chronic Liver Diseases (CLD) is Driven by Nonalcoholic Steatohepatitis (NASH) and Alcohol Liver Disease (ALD) - (06/27/22)
EASL: Real life study of bulevirtide in chronic hepatitis Delta: preliminary results of the ANRS I MIE HD EP01 HDV prospective cohort - (06/26/22)
EASL: Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 2a Study; ATI-1428 and ATI-1645 Exhibit Potent Antiviral Activity in a Nonclinical Study - (06/26/22)
EASL: Improving the pharmacokinetic profile of the hepatitis B virus core inhibitor ABI-H3733 following oral administration: results from new formulation activities - (06/26/22)
EASL: Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment-naïve patients with HBeAg positive chronic hepatitis B - (06/26/22)
EASL: Sustained 12 Week Off Treatment Antiviral Efficacy of ATI-2173, a Novel Active Site Polymerase Inhibitor Nucleotide (ASPIN), Combined With Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients, a Phase 2a Clinical Trial - (06/26/22)
EASL: Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection: interim results from the randomised Phase 2b B-Clear study - (06/26/22)
EASL: Therapeutic Vaccine JNJ-0535 Induces a Strong HBV-specific T-cell Response in Healthy Adults and a Modest Response in Chronic HBV-infected Patients VOX/VEL/SOF Effective Rescue After DAA Failure-With Limits - (06/26/22)
EASL: Efficacy and Safety of Finite 48-week Treatment With the siRNA JNJ-3989 and the Capsid Assembly Modulator JNJ-6379 in HBeAg Negative Virologically Suppressed Chronic Hepatitis B Patients: Results from the REEF-2 Study - (06/25/22)
EASL: Association between Hepatitis Delta Virus with Liver Morbidity and Mortality: A Systematic Literature Review and Meta-Analysis - (06/25/22)
EASL: Evaluating Hepatitis Delta Virus Disease Prevalence and Patient Characteristics Among Adults in the United States: An Analysis of All-Payer Claims Database - (06/25/22)